Calmette-Guérin vaccine

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:bfsLayer 4
gptkbp:bfsParent gptkb:Albert_Calmette
gptkbp:age infants
gptkbp:allows may cause false-positive tuberculin skin tests
not recommended for certain populations
not universally effective
requires trained personnel for administration
gptkbp:appointed_by intradermal injection
gptkbp:approves many countries
gptkbp:brand gptkb:BCG
gptkbp:category BCG vaccine
gptkbp:clinical_trial ongoing research
gptkbp:contraindication pregnancy
immunocompromised individuals
gptkbp:developed_by gptkb:Camille_Guérin
gptkb:Albert_Calmette
gptkbp:dosage_form single dose
gptkbp:first_introduced gptkb:1921
gptkbp:global_presence over 100 countries
gptkbp:historical_significance first vaccine for tuberculosis
https://www.w3.org/2000/01/rdf-schema#label Calmette-Guérin vaccine
gptkbp:impact tuberculosis incidence
gptkbp:is_effective_against varies by population
gptkbp:is_used_for tuberculosis prevention
gptkbp:is_vulnerable_to preventive vaccine
developed from Mycobacterium bovis
50-80% in preventing severe forms of tuberculosis
analyzed for long-term effects
assessed for efficacy in elderly populations
evaluated for safety in pregnancy
explored for combination therapies
explored for use in COVID-19 trials
investigated for use in HIV patients
investigated for use in other cancers
less effective against pulmonary tuberculosis
reduces risk of disseminated tuberculosis
reduces risk of tuberculosis meningitis
studied for immune modulation
studied for potential in autoimmune diseases
improves overall survival in bladder cancer patients
gptkbp:part_of tuberculosis control programs
gptkbp:produced_by various pharmaceutical companies
gptkbp:research_focus bladder cancer treatment
immune response enhancement
gptkbp:side_effect fever
lymphadenopathy
local reactions
gptkbp:social_responsibility tuberculosis
bladder cancer
gptkbp:storage refrigeration
gptkbp:suitable_for gptkb:WHO
gptkbp:type live attenuated vaccine